iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics-Reference-Cited by-同舟云学术

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Published:2017-03 Issue:3 Volume:18 Page:e143-e152
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Seymour Lesley,Bogaerts Jan,Perrone Andrea,Ford Robert,Schwartz Lawrence H,Mandrekar Sumithra,Lin Nancy U,Litière Saskia,Dancey Janet,Chen Alice,Hodi F Stephen,Therasse Patrick,Hoekstra Otto S,Shankar Lalitha K,Wolchok Jedd D,Ballinger Marcus,Caramella Caroline,de Vries Elisabeth G E

Publisher

Elsevier BV

Subject

Oncology

Reference35 articles.

1. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals;Kim;JAMA Intern Med,2015

2. Reporting results of cancer treatment;Miller;Cancer,1981

3. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada;Therasse;J Natl Cancer Inst,2000

4. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1·1);Eisenhauer;Eur J Cancer,2009

5. The role of response evaluation criteria in solid tumor in anticancer treatment evaluation: results of a survey in the oncology community;Liu;Eur J Cancer,2014

Cited by 1726 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for breast cancer: New strategies to enhance the patient selection and overcome therapeutic resistance;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Immunotherapeutic strategies for the treatment of colorectal cancer;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

3. Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy;International Immunopharmacology;2024-11

4. Sleep disturbance as a poor prognostic predictor in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A prospective study;Journal of Psychosomatic Research;2024-11

5. Treatment options for tumor progression after initial immunotherapy in advanced non-small cell lung cancer: A real-world study;Neoplasia;2024-11